CY1117839T1 - Γονιδιο τομ34 σχετιζομενο με καρκινο του παχεος εντερου - Google Patents

Γονιδιο τομ34 σχετιζομενο με καρκινο του παχεος εντερου

Info

Publication number
CY1117839T1
CY1117839T1 CY20161100717T CY161100717T CY1117839T1 CY 1117839 T1 CY1117839 T1 CY 1117839T1 CY 20161100717 T CY20161100717 T CY 20161100717T CY 161100717 T CY161100717 T CY 161100717T CY 1117839 T1 CY1117839 T1 CY 1117839T1
Authority
CY
Cyprus
Prior art keywords
colorectal cancer
tom34
volume
generated
thick interior
Prior art date
Application number
CY20161100717T
Other languages
English (en)
Inventor
Yusuke Nakamura
Yoichi Furukawa
Hideaki Tahara
Takuya Tsunoda
Satoshi Matsushima
Original Assignee
Oncotherapy Science, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncotherapy Science, Inc. filed Critical Oncotherapy Science, Inc.
Publication of CY1117839T1 publication Critical patent/CY1117839T1/el

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57419—Specifically defined cancers of colon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Αντικειμενικές μέθοδοι για την ανίχνευση και διάγνωση του καρκίνου του παχέος εντέρου περιγράφονται στο παρόν. Σε μία πραγματοποίηση, η διαγνωστική μέθοδος περιλαμβάνει τον προσδιορισμό του επιπέδου εκφράσεως του ΤΟΜ34 που διακρίνει τα κύτταρα του καρκίνου του παχέος εντέρου από τα φυσιολογικά κύτταρα. Τέλος, η παρούσα εφεύρεση παρέχει μεθόδους διαλογής θεραπευτικών παραγόντων χρήσιμων στην αγωγή του καρκίνου του παχέος εντέρου, μεθόδους αγωγής του καρκίνου του παχέος εντέρου και μέθοδο εμβολιασμού ενός ατόμου έναντι του καρκίνου του παχέος εντέρου.
CY20161100717T 2005-07-27 2016-07-21 Γονιδιο τομ34 σχετιζομενο με καρκινο του παχεος εντερου CY1117839T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70326505P 2005-07-27 2005-07-27
PCT/JP2006/314947 WO2007013576A1 (en) 2005-07-27 2006-07-21 Colon cancer related gene tom34

Publications (1)

Publication Number Publication Date
CY1117839T1 true CY1117839T1 (el) 2017-05-17

Family

ID=37499354

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20161100717T CY1117839T1 (el) 2005-07-27 2016-07-21 Γονιδιο τομ34 σχετιζομενο με καρκινο του παχεος εντερου

Country Status (19)

Country Link
US (1) US8674059B2 (el)
EP (1) EP1910839B1 (el)
JP (2) JP5095603B2 (el)
KR (2) KR101325194B1 (el)
CN (1) CN101278196B (el)
AU (1) AU2006273192B2 (el)
BR (1) BRPI0613970B8 (el)
CA (1) CA2616497C (el)
CY (1) CY1117839T1 (el)
DK (1) DK1910839T3 (el)
ES (1) ES2584247T3 (el)
HK (1) HK1115193A1 (el)
HU (1) HUE027330T2 (el)
PL (1) PL1910839T3 (el)
PT (1) PT1910839T (el)
RU (2) RU2449020C2 (el)
SG (1) SG163614A1 (el)
SI (1) SI1910839T1 (el)
WO (1) WO2007013576A1 (el)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012519470A (ja) * 2009-03-04 2012-08-30 オンコセラピー・サイエンス株式会社 Ｖａｎｇｌ１ペプチドおよびそれを含むワクチン
TWI485245B (zh) * 2010-01-25 2015-05-21 Oncotherapy Science Inc 經修飾之ｍｅｌｋ胜肽及含此胜肽之疫苗
WO2012032763A1 (en) * 2010-09-07 2012-03-15 Oncotherapy Science, Inc. Vangl1 peptides and vaccines including the same
UA110119C2 (xx) * 2010-12-02 2015-11-25 Пептиди tomm34 та вакцини, що їх містять
MX355759B (es) 2011-10-28 2018-04-27 Oncotherapy Science Inc Peptidos topk y vacunas que incluyen los mismos.
US20150359864A1 (en) 2012-03-09 2015-12-17 Oncotherapy Science, Inc. Pharmaceutical composition containing peptides
EP3187191B1 (en) * 2014-08-26 2020-04-08 NKMAX Co., Ltd. Antibody for recognizing specific motif of wls protein, and pharmaceutical composition containing same

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US5785973A (en) * 1988-02-01 1998-07-28 Praxis Biologics, Inc. Synthetic peptides representing a T-cell epitope as a carrier molecule for conjugate vaccines
CA2047191A1 (en) * 1989-02-17 1990-08-18 Hendrik M. Geysen Method for the use and synthesis of peptides
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5679647A (en) 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
US5804566A (en) 1993-08-26 1998-09-08 The Regents Of The University Of California Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides
US5739118A (en) 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
US5736524A (en) 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
US5922687A (en) 1995-05-04 1999-07-13 Board Of Trustees Of The Leland Stanford Junior University Intracellular delivery of nucleic acids using pressure
AU6632496A (en) 1995-08-03 1997-03-05 Rijksuniversiteit Te Leiden Cell derived antigen presenting vesicles
US5840839A (en) * 1996-02-09 1998-11-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein
US5853719A (en) 1996-04-30 1998-12-29 Duke University Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA
WO1998004720A1 (en) 1996-07-26 1998-02-05 Sloan-Kettering Institute For Cancer Research Method and reagents for genetic immunization
FR2766205B1 (fr) 1997-07-16 2002-08-30 Inst Nat Sante Rech Med Nouveau procede de sensibilisation de cellules presentatrices d'antigene et nouveaux moyens pour la mise en oeuvre du procede
US7166573B1 (en) * 1999-05-28 2007-01-23 Ludwig Institute For Cancer Research Breast, gastric and prostate cancer associated antigens and uses therefor
US20020137683A1 (en) 2000-01-03 2002-09-26 Hogan Kevin T. C-ski oncogene-derived peptides for prevention, treatment, and diagnosis of cancer
US7700359B2 (en) * 2000-06-02 2010-04-20 Novartis Vaccines And Diagnostics, Inc. Gene products differentially expressed in cancerous cells
US20040181344A1 (en) * 2002-01-29 2004-09-16 Massachusetts Institute Of Technology Systems and methods for providing diagnostic services
AU2003254950A1 (en) * 2002-08-26 2004-03-11 Kirin Beer Kabushiki Kaisha Peptides and drugs containing the same
CA2511907A1 (en) * 2003-01-06 2004-07-22 Wyeth Compositions and methods for diagnosing and treating colon cancers

Also Published As

Publication number Publication date
CN101278196A (zh) 2008-10-01
PT1910839T (pt) 2016-07-14
RU2011127868A (ru) 2013-01-20
ES2584247T3 (es) 2016-09-26
RU2449020C2 (ru) 2012-04-27
EP1910839A1 (en) 2008-04-16
BRPI0613970B1 (pt) 2019-10-29
CA2616497C (en) 2016-06-07
SI1910839T1 (sl) 2016-06-30
JP2012125248A (ja) 2012-07-05
JP5095603B2 (ja) 2012-12-12
HK1115193A1 (zh) 2008-11-21
KR20080040738A (ko) 2008-05-08
CN101278196B (zh) 2013-05-15
DK1910839T3 (en) 2016-07-04
KR20130087639A (ko) 2013-08-06
KR101325194B1 (ko) 2013-11-06
CA2616497A1 (en) 2007-02-01
US8674059B2 (en) 2014-03-18
HUE027330T2 (en) 2016-09-28
PL1910839T3 (pl) 2016-11-30
RU2008107318A (ru) 2009-09-10
AU2006273192B2 (en) 2011-09-01
SG163614A1 (en) 2010-08-30
US20090214571A1 (en) 2009-08-27
BRPI0613970A2 (pt) 2011-02-22
JP2009502732A (ja) 2009-01-29
AU2006273192A1 (en) 2007-02-01
BRPI0613970B8 (pt) 2021-05-25
WO2007013576A1 (en) 2007-02-01
RU2526196C2 (ru) 2014-08-20
EP1910839B1 (en) 2016-04-27

Similar Documents

Publication Publication Date Title
CY1117839T1 (el) Γονιδιο τομ34 σχετιζομενο με καρκινο του παχεος εντερου
CY1120423T1 (el) Β7-η1 και pd-1 στη θεραπεια του καρκινωματος νεφρικων κυτταρων
ATE419391T1 (de) Gene und polypeptide in verbindung mit menschlichen pankreaskarzinomen
ZA202000935B (en) Methods and materials for assessing and treating cancer
CY1124144T1 (el) Συνθεσεις και μεθοδοι για θεραπεια εγκεφαλικου επεισοδιου σε ενα υποκειμενο επι ταυτοχρονης θεραπειας στατινης
CY1114132T1 (el) Γαστροανθεκτικες φαρμακοτεχνικες μορφες που περιεχουν ριφαξιμινη
ATE508202T1 (de) Verfahren zur diagnose von brustkrebs
CY1116967T1 (el) Συνθεσεις και μεθοδοι για θεραπευτικη αγωγη και διαγνωση καρκινου
WO2012054589A3 (en) Conduit-containing devices and methods for analyte processing and detection
DE60214134D1 (de) Modifizierte psma-liganden und deren verwendung
WO2007013575A3 (en) Method for diagnosing and treating renal cell carcinoma
WO2005028675A3 (en) Methods for detecting, diagnosing and treating hepatocellular carcinomas (hcc)
MX2022005123A (es) Tratamiento basado en anti-cd47 y anti-cd20 para cancer hematologico.
ATE419516T1 (de) Monoklonale antikörper und zelloberflächenantigene zum nachweis und zur behandlung von kleinzelligem lungenkrebs (sclc)
CY1120063T1 (el) Αντισωματα κατα του ανθρωπινου dlk-1 που εχει δραση κατα των ογκων in vivo
CY1112288T1 (el) Θεραπεια του καρκινου με αντισωματα κατα της il-1a
BRPI0813364A2 (pt) Métodos de diagnóstico e tratamento de câncer.
CY1118663T1 (el) Μεθοδος αναγνωρισης κινδυνου για διαταραχη του θυρεοειδους
CY1122202T1 (el) Προσδιορισμος κινδυνου για θεραπεια αντιβιοτικων σε ασθενεις οι οποιοι υποφερουν απο πρωτοπαθη μη μολυσματικη νοσο δια καθορισμου του επιπεδου προκαλσιτονινης
TW200643176A (en) ZNFN3A1/breast cancer related gene ZNFN3A1
CY1110538T1 (el) S-μιρταζαπινη για τη θεραπεια των εξαψεων
CY1124881T1 (el) Στρωματωση γονοτυπου στην θεραπεια και προληψη του διαβητη
WO2007013360A3 (en) Pancreatic cancer related gene cst6 and gabrp
EP1899726A4 (en) METHODS FOR DIAGNOSING AND TREATING CEREBROVASCULAR EVENTS BASED ON NR2 PEPTIDES
WO2004038045A3 (en) Method for diagnosing diffuse-type gastric cancer